Stocks Surge To Start Week… And Structure Therapeutics CEO On Weight Loss Space 3/24/25

24 Mar 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" Episode - Stocks Surge To Start Week… And Structure Therapeutics CEO On Weight Loss Space (3/24/25)

Overview In this episode of "Fast Money," hosted by Melissa Lee, a panel of expert traders discusses the recent surge in stock markets amid hopes of softened tariff policies from President Trump. The episode also features an interview with Ray Stevens, CEO of Structure Therapeutics, who shares insights about the company’s developments in the weight loss drug sector.

---

Key Topics Discussed

Market Surge and Tariff Policies

  • Stock Market Performance: Major averages saw significant gains, with the NASDAQ climbing over 2%. The S&P experienced its best Monday since October 2022.
  • Sector Performance:
  • Leading Sectors: Consumer discretionary, communication services, and financials.
  • Lagging Sector: Utilities ended the day in the red.
  • Market Sentiment: The panel expressed skepticism about the sustainability of the current rally, citing ongoing uncertainty regarding tariffs and economic conditions.

Panel Insights

  • Guy Adami: Skeptical of the rally's longevity; believes it is short-lived due to unresolved uncertainties concerning tariffs.
  • Tim Seymour: Noted that while the market has shown a bounce, the fundamentals remain unchanged, indicating potential volatility ahead.
  • Karen Firestone: Emphasized the importance of the upcoming earnings season and conservative guidance likely to be issued by companies.

Earnings Predictions

  • Discussion on the earnings potential of the S&P 500. Some strategists predict earnings could fall to $230 per share, which would reflect high valuations based on historical trends.

Structure Therapeutics Interview with Ray Stevens

  • Company Overview: Structure Therapeutics is focused on developing oral weight loss medications. Their lead candidate, Leniglipuron, aims to provide a more convenient alternative to injectables.
  • Development Timeline: Anticipates phase two readouts by the end of 2025, with a focus on accessibility and patient flexibility.
  • Competition Analysis: Stevens highlighted the competition with Eli Lilly's medications and the importance of offering patients options.

Market Trends in Pharmaceuticals

  • Eli Lilly vs. Novo Nordisk: Discussion on the contrasting performances of these companies in the weight loss drug market, with analysts forecasting strong sales for Lilly’s products.

BYD's Milestone Achievement

  • Sales Growth: Chinese EV maker BYD surpassed $100 billion in revenue in 2024, outperforming Tesla in significant sales metrics.

Disney's Box Office Struggles

  • Snow White Release: The film's poor performance at the box office was attributed to controversy and high production costs. Analysts are questioning its future in the Disney lineup.

---

Key Takeaways

  • Market Dynamics: While the stock market rallies due to potential tariff reductions, underlying economic uncertainties remain.
  • Pharma Innovations: Structure Therapeutics seeks to disrupt the weight loss market with oral medications, emphasizing patient accessibility.
  • Disney Resilience: Despite recent setbacks, analysts maintain that Disney's broader portfolio and streaming services may mitigate losses.

Final Thoughts Investors are advised to remain cautious about the current market rally, acknowledging that while there are opportunities, volatility and uncertainty continue to loom. Companies in the pharmaceutical and entertainment sectors are pivotal to watch as they navigate market challenges and consumer demands.

---

For more detailed insights, listen to the full episode of "Fast Money."

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq market site in the heart of New York City's Times Square, this is Fast Money. Here's what's on tap tonight. A strong start to the week. Major averages rallying on hopes of a softer tariff policy out of D.C. Can the strength be sustained and how much higher can we go from here? And a box office bus. Disney's trouble plague retelling of Snow White failing to impress on ticket sales. What's it mean for the studio and the competition? Plus, why the chart master says Uber can drive higher. BYD hits a major milestone faster than Tesla. And the race for a weight loss pill will get the very latest on developments from the CEO of Structure Therapeutics.

0:37I'm Melissa Lee, coming to you live from Studio B at the NASDAQ on the desk tonight. Tim Seymour, Karen Freinerman, Dan Nathan, and Guy Adami. We start off with the markets ripping higher to kick off the week. President Trump suggesting many countries could get breaks on tariffs. The NASDAQ up more than 2%. The S &P is seeing its best Monday since the bear market ended in October 2022. Consumer discretionary, communication services, and financials leading the way today with utilities. the only sector to finish in the red. Among the single stock winners, Tesla, United Airlines, AMD, and Palantir.

1:06But the three major indices are still negative for the month, and only the Dow is in the green, albeit barely for the year. So should you have faith in this rally that we've seen recently? Are you a believer, Guy? Hi, Mel. Hello. Happy Monday. No, I'm a believer in a lot of things. I was just contemplating a lot of things. In this rally? No, I'm not. And, you know, we had a conversation last week. You know, we thought it got down to levels where theoretically technical support, you should see a bounce within this sort of counter trend rally. We're seeing it now. If you want to do the math and play that game, I think 58 and a quarter makes a lot of sense.

1:40That's a 50 percent retracement of the all time high we saw in February in this recent low of 55.05. So the rally makes sense. I think, again, probably oversold conditions, but I think it's going to be somewhat short lived. I could see a day tomorrow where we open on the highs and close on the lows. Yeah. And the other thing is it doesn't really clear up the uncertainty that was causing the downward volatility over the last month or so. I mean, this is the kind of on again, off again. I mean, we've seen this before. We were Trump 1.0. We saw, you know, we're going to do this. By the way, this is not something he ran on.

2:08I mean, this was not a reason that he got elected. This wasn't one of the main reasons. And so I just find it really interesting that this is one of the things that's kind of causing not just on Wall Street, but on Main Street. Right. And so when we get to earnings season really in a few weeks, which is pretty interesting, I think we're going to see that Q1 activity was probably slower than we would have expected. And the guidance for Q2 is not going to be particularly great. So you have to start asking yourself is that if we don't get any clarity sometime soon, this volatility is going to be here to stay.

2:38And, you know, it's probably not doing anybody any favors when you think about the economy coming into the year. It was pretty decent. I mean, saying that the tariffs are going to be softer, that's nice. But the uncertainty is still there. If you're a CEO, you still don't know how to plan. You don't really know what the tariff situation will be. And, I mean, it might even be worse. Isn't it better to just know and then you can deal with what you know as opposed to being pushed around constantly? Markets hate uncertainty more than they hate bad news. The scepter of bad news is well worse. So I agree with that.

3:07Although, I mean, there was not maximum fear, but a lot of fear, a lot of fear already. And so to have them come back a little bit is great. Interesting. We saw that data this morning, pretty hot in a different market where on a different day where we weren't talking about maybe the tariffs not being as bad. I think what that did to interest rates may have actually had the market go south. Right. Because I think this sort of that hot, those hot numbers take the Fed out of the equation a little bit more, I think. So, I mean, it was a nice bounce. Right to your point. I mean, it's not shocking at all.

3:41We really were oversold. You know, I'm always long. So a day like today is great. But I've had 17 bad days. So, you know, whatever. We're back to, you know, maybe going down. Two weeks ago. Yeah, two weeks ago. I do think the tariff thing is important, though. But I think that we're still going to see companies, when they come out, give conservative guidance. Yeah, I would answer just through the lens of the markets. If you think that this is that the Trump put, which I thought was around 5 ,200 on the S &P, if the strike price is now 56, it gives markets a reason to say. And this is what markets do, whether it's the Fed, whether it's the administration saying there's a level in which we'll have so much pain, even though they're telling us to just endure a little pain.

4:21This is kind of what it felt like. And everyone is documenting or identifying the oversold conditions we had. We all know where RSI's got, even on the S &P as an index kind of mid last week. We had a quad witch on Friday. I mean, it's set up for good news to take markets a lot higher, especially the biggest stocks in the world, which didn't necessarily go crazy other than if you look at what semis did. But it tradable bounce and whatnot. And I know we're going to have a great conversation with Mike Wilson in a second. But let's just be clear. The S &P has already rallied over five percent off of that intraday low.

4:52So half of you think we're going to have a 10 percent move in the S &P. And if you do, half of it's done. And if you were selling on the day that actually it turned around, you're not feeling so great. So I don't know that the fundamentals have changed at all. That's why it will be interesting to hear what some of the strategists have to say. Karen brought up yields, I think, correctly. I mean, we're back above 430 again in the 10-year. And does it make sense? Yeah, it makes sense to me. I think to a certain extent, the broader market sell-off led people into the bond market, sort of a flight to perceived quality.

5:22The fact that maybe there's risk on the last couple of trading sessions, Maybe money's coming out of the bond market, I think, correctly. So at a certain point, people are going to start talking about the bond market again. It's probably a lot sooner rather than later. You know, as the silver lining guy on the desk, it is interesting that the S &P is only down 2 percent. Right. So if you think about that, like we've taken a lot of the euphoria out of the fateful eight, as Karen calls them. And we really, you know, are kind of back at a place where you want to look at some other sectors that may be part of the leadership going forward.

5:51It's been my belief, though, the only way we're going to get back to those prior highs and probably get through them is if the fateful eight really does take us higher. So we've seen earnings come down for them at least a little bit over the last couple quarters. And if you see that start to inflect higher and maybe you kind of lay off a little bit of that CapEx, then that will be very helpful for S &P earnings. I saw a strategist come out and say they think there could be two hundred and thirty dollars in earnings. If we have two hundred and thirty dollars in earnings for the S &P 500 this year, then we are way, way expensive.

6:21relative to, you know, the last five and ten years. So, again, we better hope not for that, but we better get more clarity on the tariff situation or we're going to continue to see some kind of, you know, I think tough sledding for the S &P 500. I'm glad you mentioned the eight largest tech stocks. Yeah. I refuse to call anything. Does Dan get paid every time he says fateful eight on TV? I feel like, right? He gets some kind of kickback. I just wanted to see him. I just wanted to sound twisted. Sit on me. Why don't call him fateful eight? There is an argument being put forth by J.P. Morgan that there's been a lot of de-risking that has gone on in the tech trade.

6:54And so, therefore, the likelihood of another major pullback has gone down because the positioning is sort of right-sized now. I don't think there's any question about that. And you can see that in the fund flows. And Bank of America does a nice job with that. Michael Hartnett's notes have chronicled where we had it. And we actually had actually a lot of people step in on Friday after a couple weeks. And we know where foreign stocks or the MIGA stocks, Dan, actually have actually outperformed the rest of the world, making international great again. I would just also get back to the data. I'm not worried about the bond market unless it yields to the downside.

7:25I'm not worried about five set four seventy five on the 10 year. I'm not even that worried about five percent. I think we're at a place here. You got composite PMIs this morning. So you get a little bit of manufacturing, a little bit of services. And it was a great number. It was a lot better than expected. I think it came in at fifty three six versus fifty one four or expected. The problem is that some of this is just front running on tariffs and some of that services industry. But what you did hear from the business confidence element of this is that business confidence is nowhere. From a trading perspective, there's some things that I think you don't get too far away from, which indicate that there's a lot of fear.

7:57You don't get away from gold. You don't get away from from industrial metals. You don't get away from the places I think are both measuring inflation and uncertainty. And I think those are trades that even on days like this, you're getting another shot to get back in there. So in terms of this tradable rally or whatever we want to call it, short-lived rally, rally for now, not for the long term, is it just into earnings? Is it just until earnings season starts when we start getting the CEO commentary but all the uncertainty out there, how, you know, the consumer is still weak or uncertain, et cetera?

8:26Well, I feel like the banks are the most important ones because it's not just how they're doing. It's how they look through in the whole economy. So that's important. And I also think they're maybe a little less likely to sandbag. So that'll be really important. One thing I did today, I had bought some J.P. Morgan call spreads. I took them off. That was it. But that's, to me, the most important set of earnings. Yeah, you know, I think there's still weakness in the consumer that tariffs, no tariffs. I mean, we're going to get more headlines, obviously, from now until April 2nd. But I think the underlying cause, in my opinion, the headline cause I get, the underlying cause is a weakness in the consumer and a weakness in the economy.

9:04despite some of the numbers we might be seeing. And Tim says he's not concerned. I get it. If rates go higher because things are improving, that's fine. But if rates are going higher and things are deteriorating, that's not particularly good. Well, Morgan Stanley's out with a new bullish call saying the beaten up MAG-7 names could be ready to rebound. Mike Wilson's a firm's chief U.S. equity strategist and chief investment officer. He joins us now. Mike, great to see you. Good to see you, too. So this is a tradable rally for how long? Well, it has been. I guess, you know, look, I think we're just marking to market with respect to, I think we came into the year a bit more worried about the first half.

9:42We had a range of sort of$5 ,500 to$6 ,100, and we hit the low end of that range. So, you know, the fact that we bottomed right on that number, I guess, made us feel better. That technical level was real support. But really, at the end of the day, I mean, everybody's talking about tariffs right now. But the reason the markets are lower over the course of the last three or four months has nothing to do with tariffs. It's mostly to do with the fact that earnings revisions have rolled over, the Fed stopped cutting rates, you had stricter enforcement on immigration, you have Doge, which all those things are growth negative.

10:13And then tariffs is just kind of the final piece that kind of got people really kind of bearish at the end. And I would say the thing that really got the S &P going down at the very end was when it became clear that the president does not care about the stock market, at least for now. And that lack of a Trump put was like really new news to people. So we felt like all of that sort of capitulation was good at 5 ,500. It started out with a low-quality rally, which is what we expected, meaning a short squeeze. And then what we noticed is that the revision factors on the MAG-7 are actually starting to stabilize a bit.

10:47So the last couple of days, those stocks have acted better. And that can take the index higher. Like how high? 5 ,900. So we're almost there. It's halfway done. I mean, the move has kind of already happened. I think the bigger moves are going to happen in these lower quality areas where the short base is still pretty stiff. And ultimately, though, I think I agree with a lot of the commentary you had on the panel there, which is that it's going to remain volatile through the end of the second quarter. So whatever rally we're getting now, we think probably ends up fading into earnings into May and June.

11:19And then we'll probably make a more durable low later in the year. A durable and new low. Like we haven't seen the lows for the year. Potentially a low. Let's put it this way. I think the chance of us making a new high in the first half is very, very low. OK, could we make a new high in the second half of the year as people look forward to 2026? Yeah. Do we have to make a new low in the S &P 500? I have no idea. But I can tell you this is that I think that it's going to be a trading environment at a minimum. OK, that's your best case scenario between now and probably the end of June and into the summer.

11:49And that's why we're here on Fast Money. You know, our job is to be both, you know, we have views on the long term and we have views over the short term. And our views in the short term, I think, have been pretty accurate. Yeah. So, Mike, you came out with that note this morning. But last week's note, so every Monday you come out with it, was also hinting to this. You were kind of suggesting the fact that some of the names that you really care about from an earnings perspective were kind of getting overdone to the downside. If you think of the fateful eight, they were doubling up the downside that we saw in the S &P 500.

12:19So on a day like today, it's kind of interesting when you see Apple, Microsoft, Broadcom underperform. Is that sort of price action, is that the sort of thing over the next few days, if we just don't see them continuing to participate, that you might kind of go to a more bearish stance? Well, there's dispersion in the MAG-7, Faithful 8, whatever you want to call them. I mean, half of the group was quite positive today. I mean, Tesla had a massive move. So, look, I think the barbell to own right now for this trade has been MAG-7, but also low quality. And that's what this is kind of reflecting.

12:57I don't think the market's trading off of fundamentals. It's more about technicals. It's more about the flows, where the short base is greatest. But the one piece that we felt good about this week was that the MAG-7 or Faithful-8 revisions are starting to sort of bottom out a bit. And the other trade that we advocated this week was that the U.S. could have a relative move back against Europe. because as we go into second quarter earnings, right, now with the dollar weaker, that's going to be a headwind for European earnings and actually a tailwind for some of the larger cap names in the U.S. Look, these are the trades that, you know, this is what we're being given, right?

13:32So we have to take advantage of these trades when we see them. Hey, Mike, it's Tim. So it sounds like you're a little more negative on the MIGA trade, and that's making international great again. But my question for you is, what part of your view here is somewhat non-consensus? or I'd be just curious to know, like, which of these subsectors do you actually think we're really going to have some impressive earnings growth? I mean, the energy sector is one of these places, too, where I think you really have seen some non-correlations, some surprise resilience and actually some earnings growth. It's not a big deal, probably, even to someone like you, because it's it's four to four and a half percent of the S &P.

14:02But tell me about health care. Tell me about, you know, which also looks like it's really had a nice recovery off of some fundamentals and some headlines that were not so good. Help us drill a little deeper than just this is a trading rally. That's right. I mean, on a more core basis, you know, we've been very focused on earnings revisions where they've been good. And that's been financials, some of the software stocks, consumer services still look pretty good. And, of course, some of the media entertainment area, not the ones people are excited about, but more like your telcos and cable companies, quite frankly.

14:31And then energy has been a group we've been overweight. It's finally working now here this year. Health care is very idiosyncratic, as you know. So, you know, it's a mix. It's a real mix, and it's more idiosyncratic. I think what I can tell you is that our work suggests that you still want to stay up the quality curve for your core portfolio. What we've been talking about the last couple of weeks is more of the trades that we sort of like in here. But those four groups I mentioned before, financial software, consumer services, and some of the media entertainment, those would be the core of our portfolio right now from a revision standpoint.

15:02And then we'll be looking for parts of the market that can benefit into 2026. I think it's a little premature for areas like energy and materials have a sustained move because I'm not really a believer yet in global growth accelerating. But those are two areas I think could have a really good second half of the year. Mike, great to speak with you. Thanks. Mike Wilson, Morgan Stanley. What do you think of this core? Tactical. No, the court. It all makes sense what he's saying. He's looking for an overshoot to fifty nine hundred. We talked about fifty eight in a quarter. I get it. I think close enough for government work type of thing.

15:34I do think if I'm reading between the lines, potentially another leg lower before we reaccelerate in the back half of the year. That all makes sense to me. But I'll add one more group. I think energy very quietly is going to surprise people to the upside. The XLE, I think, closed north of 92.5 or so today. And that's going to start flirting with levels we saw 11 or so years ago, I think, very quietly without people paying attention. So energy to me is the place to be. You've got energy in your acronym. I do. Remind us which letter it's supposed to be. E. It's E for the OIH. I don't know why this is so different.

16:04Yeah, it's two years in a row. It's elementary, Watson. Exactly. So, yes, I like, I mean, you know, it has, I just, the valuations are so ridiculously cheap. That's been the case for a while, though. But I'm a believer. And now to one of South Korea's biggest companies, Hyundai, expanding their U.S. presence. A multibillion-dollar investment was announced at the White House this afternoon. Let's bring in CNBC's Seema Modi for the details on this. Seema. Melissa, South Korea's Hyundai announcing a$21 billion investment in U.S. manufacturing that includes a new plant in Louisiana that will produce about 2.7 million tons of high-quality automotive steel a year for Hyundai and Kia motor cars.

16:43The announcement was made by President Trump alongside Hyundai's chairman at the White House this afternoon, in which the South Korean conglomerate also revealed plans to purchase$3 billion worth of U.S. LNG. It is seen as a way to level the U.S. trade deficit with South Korea. Trump adding that the investment in U.S. onshoring is a clear demonstration to him that tariffs work, suggesting that this is a blueprint for other companies looking to avoid higher levies on U.S. imports. Unclear if Hyundai's investment announced today gives South Korea an exemption from the April 2nd reciprocal tariffs.

17:17However, it does follow a string of high-profile U.S. investments in recent months, from the likes of Taiwan Semiconductor, Apple, Japan SoftBank, Honda. We now wait to see, Melissa, how quickly that money is spent. Seema, thank you. Seema Modi. Can you imagine if all these companies opened their own steel plants to supply their own companies to manufacture their own cars? It sounds wildly inefficient. It really does. It's not how it goes down. That's why it's kind of a surprise. Also, if you look at the auto industry, companies like BMW, we talked about this on this show, which has a major plant in South Carolina, we're already doing a significant amount of their production.

17:55This is great news. It makes for great headlines. And the question is how much of this is truly incremental. Yeah, and how much of it, how much of the money will actually be spent on these projects in the end? That's a big question. Well, yeah, the$500 billion one is sort of top of mind. And was it true? I don't know. Let me know whether this Hyundai was already, I'm sorry, that was SK today, right? Which one? Which was the release they just did? Hyundai. Hyundai. Hyundai. Sorry, it was Hyundai. That that had already been planned prior to this announcement today. Is that correct or no? Yeah, most of them.

18:34I'm not sure. Nor am I. But I like the pronunciation of Hyundai. Tim looked at me. I don't know anyone here is pronouncing it Hyundai other than you, but that's fine. But I do that often with words. Ken's probably the one person who's been to Seoul. You've been to Seoul? I've been to Seoul. You've been to Seoul? I have not been to Seoul. He's the ambassador. Oh, you are. Oh, he's the ambassador. Let's trade the globe here. We're so off base now. Let's move on. Coming up, we lost drug makers on opposite sides of the scale this year. As Eli Lilly and Novo Nordis look to round out Q1 in very different places, what Wall Street sees in the store for this space, and can a new China deal help pack on the pounds for one of these names?

19:10Plus, Chinese EV maker BYD charging past the competition, the company hitting a major sales milestone. How this name sacks up against the U.S. competition. Next, don't go anywhere. Fast Money is back in two.

19:31Welcome back to Fast Money. We've got an earnings alert on KB Home. Shares dropping after missing EPS and revenue expectations. Pippa Stevens has got the details. Hi, Pippa. Hey, Melissa. EPS coming in at$149. That was nine cents short of estimates with revenues of$1.39 billion also short. The company also cut its revenue guidance for 2025, saying, quote, consumers are working through affordability concerns and uncertainties related to macroeconomic and geopolitical issues, which are causing them to move slowly in their home buying decisions, adding that demand at the start of the spring selling season is, quote, more muted than what we have seen historically.

20:06Now, on the call just now, the company is saying it's started to move to longer-term contracts in anticipation of tariffs. Melissa? All right, Pippa, thanks. Pippa Stevens, stock down 6.7 percent here. Guy? Average selling price, the guidance is for$480 to$495. I mean, we've been north of$500 for a while. And then if you look at deliveries, I mean, that was disappointing, I think. I mean,$2 ,770 as opposed to$3 ,000 she was looking for. So there's a deterioration here. And it makes sense. If the consumer is slowing down, it's going to manifest itself in these names. We've been saying it for a while.

20:40I know Tim is on this story as well. To me, it's not about interest rates. It's about the health of the consumer or lack thereof. I think these stocks continue to go lower. Also, the optimism around the jobs market is— Can't be good. Right, exactly. Like, even when you switch jobs, you're not necessarily going to a better-paying job anymore. And that's a big change in consumer psychology from what we've experienced recently. Well, maybe that's why the cancellation rate is much higher than expected. It was 13.3 they were looking for. It came in at 16. All right. Let's move on to Lilly rising over 3 percent with UBS forecasting higher Q1 sales of its blockbuster obesity drug Zetbound.

21:13Analysts highlighting that 70 percent of new to brand prescriptions are going to Zetbound rather than Novo Nordisk and Wigobi. Meanwhile, Novo shares falling 2 percent even after inking a deal for a new weight loss candidate from Chinese biotech United Therapeutics, or I should say United Laboratories, excuse me, very different companies, United Laboratories. The deal, worth up to$2 billion, marks Novo's latest attempt to close the gap with Lilly in the weight loss space. Basically, UBS is saying there's probably going to be some upsides to Lilly in Q1 while Novo remains flat. And this move to ink this deal with it, it's very little money up front.

Read the full transcript

21:47It's$200 million with$1.8 billion potentially in milestone payments later down the road if they are met. But it sort of underscores this investor perception that Novo has a real pipeline problem when it comes to the obesity drugs. Yeah. And if you look at their recent results on Redefined 2 and where they're comparing essentially to ZepBound, you know, you've got a dynamic here that I really think there's some concern here, whether people believe that the efficacy was really as good as Lilly or that it's actually not that far off and therefore is worth it to me in terms of relative value on the stocks.

22:21It's worth it. I still I still struggle with the sell off that Novo has had relative to Lilly and relative to itself, given that I think that the growth numbers are still fantastic. The valuation isn't cheap, by the way. But I think if you look at it, they're still supplying more than Lilly in terms of the world's GLP one. And you're in it now. I am. Yeah, I bought some Lilly. I thought it was a great trade, you know, five bucks down like four and a half. That's not such a particularly good trade. You, on our midday call, you talked about the perception of maybe this deal is a sign of inadequacy, not them moving forward.

22:56Like, what do they have? They've got to do something, a bit of desperation. Like an acknowledgement that they've got to shore up the pipeline. I mean, this is supposed to be the answer to Lilly's retitrutide, which is a more efficacious injectable drug. But don't forget, Lilly's also got the oral candidate coming down the pike. So they're stacked up against a lot of different potential downside catalysts Plus muscle a stroke. Right. Exactly. Novo's been cut in half. I mean, we talk about it all the time. I thought it was going to stop in the low hundreds, high 90s. Obviously, it did not. We're trading now in the levels that we took off from in the summer of 2023.

23:29I mean, you want to play the valuation game? I would have played that$25 ago, but more so now. I mean, I think this is – there is going to be a catch-up trade at some point. The bad news is going to bait. You're going to want to own NVO. Yeah. You know, just like the generative AI trade might have – you know, fever might have broken, it's clearly broken here. If you look at like the XLV where, you know, Lilly is what, 12, 13 percent or so, it's trading at the exact same spot it was last year at this time. So, you know, the valuation is going to become an issue in Lilly. And, you know, I think Tim just mentioned that, but there's probably better ways to play it.

23:59And some of these smaller names are going to be making, you know, more innovations about whether it's, you know, prescribed for this, that, the other thing. And obviously the orals are being one. There's a lot more fast money to come. Here's what's coming up next. It's not just Novo and Lilly how one pharma competitor is taking on the weight loss drug space and the advantage it has over the competition in the pill space. We'll talk to the CEO of Structure Therapeutics next. But first,$100 billion for BYD. How the Chinese EV maker just surpassed a major sales milestone as Tesla looks to recharge after a record nine-week losing streak.

24:35You're watching Fast Money, live from the Nasdaq market side in Times Square. We're back right after this.

24:49Welcome back to Fast Money. Chinese electric automaker BYD jumping today after announcing it surpassed$100 billion in revenue in 2024. The company being Tesla to that mark, even with lower-priced vehicles aimed at undercutting the increased competition in the China market. BYD's revenue up nearly 30 percent versus 2023, while Tesla's increased just one percent. Tesla leading the S &P 500 today, by the way, higher, up nearly 12 percent. It has got beaten up, though. To your point, the ones that were beaten up most have jumped the most. Well, this is an interesting story because obviously China has been a huge part of the Tesla growth story.

25:24And BYD is a company that's obviously, you know, Buffett is a shareholder in this company. And they had about the same amount of sales as Tesla did last year as it relates to EVs. and hybrids. And I think that's interesting to note that Tesla and Elon Musk have put a stake in the ground. They will not make hybrids. And so if you reach a certain point of saturation when it comes to EVs, then a hybrid could be sort of interesting. I think that on an innovation standpoint, they have a lot more cars. They introduce them quicker. They just released a car that has 250 miles that could be charged in five minutes.

25:56They're giving away, I don't know if it's full self-driving, but it's advanced assistance. And a big part of the Tesla story going forward is that they're going to get, I don't know, hundreds of thousands of people to pay $10 ,000 for full self-driving that hasn't already been approved. So I just think this is an interesting race to watch. And they also are very clear about global expansion. While it cannot happen in the United States because of the tariff situation, there are probably other markets that would gladly have a cheaper EV with free self-driving features in every model, including one that's below$10 ,000.

26:28And they know it. And even if it's not the U.S., they know it's Europe. and they're talking about building a third plant there. They're talking about dynamics that I think will make it a global brand. And it just gets back to valuation for me. I'm along BYD in my ETF. And to me, you're one-time sales. I mean, again, however you want to do this, this is a company that I think has the scale and the ability to maybe appeal in ways that Tesla doesn't at a time when this is unrelated to what Tesla is doing. And Tesla's, by the way, Tesla rallies today as a market proxy. Let's really be clear. And I'm not sure that's what you want as a Tesla shareholder.

27:00Yeah, but it was pretty clear. Listen, I thought it could get down to 240 Tesla. It overshot that we got down to the October lows, which in retrospect makes sense. But you were looking for a bounce. We actually talked about this last week as well. And I think 285 is a bounce level. It got damn close today. 285 is sort of the 200-day-ish moving average, and it comes where the uptrend line was broken. So I think there's still room to the upside here. Maybe it overshoots, but I don't think their woes are over by any stretch. Coming up, Snow White's not-so-bashful backlash. The sleepy Fox office numbers for Disney's latest live action movie and why audiences aren't too happy about the changes.

27:37We'll explain when Fast Money returns.

27:42Missed a moment of Fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

28:01Welcome back to Fast Money Stock, surging to start the week. As President Trump says, he may give a lot of countries breaks on reciprocal tariffs. The Dow climbing nearly 600 points, the S &P up almost 2 percent, and the tech-heavy Nasdaq jumping more than 2 percent, led by Tesla's 12 percent move higher. That stock also helping the consumer discretionary sector lead today's action. The XLY up nearly 4 percent, its best day since November of 2022. And Strategy, formerly known as MicroStrategy, jumping more than 10 % today. Michael Saylor's company scooping up another$500 million worth of Bitcoin.

28:34It's now got over half a million tokens of the cryptocurrency. The broader crypto space moving higher today as well. Meantime, Disney's live-action remake of Snow White hasn't been much of a fairy tale, plagued by controversy before it hit theaters and flopping at the box office this weekend. Everything from the casting to changes to the storyline has been scrutinized. Disney shares are down 13 percent over the last year, but can it score a comeback? CNBC's Julia Morrison's got more. Julia, what went wrong? Well, the film's$43 million U.S. debut was the worst of any of Disney's live action remakes, and production and marketing costs ballooned to a reported$350 million for Snow White due to the pandemic and strikes and other issues that arose.

29:20And controversies included calls for a boycott after the star criticized the president's deportation policy. She later apologized. But Snow White may go on to deliver over the long run. It did open better than Mufasa, which went on to gross nearly$720 million worldwide. And there is very little competition at the box office for other PG films for the next few months. Plus, it could turn out to be valuable content for Disney+. And it's unlikely to impact Disney's box office dominance. Last year, Disney was the first studio to top$5 billion at the box office since before the pandemic. And this year, Disney has 14 theatrical releases, four more than last year, including two more Marvel films, another Avatar sequel, a Pixar film, and a live-action Lilo and Stitch, which could be a blockbuster.

30:09Though the original was released 23 years ago, Disney tells me that Stitch is one of its fastest-growing consumer products franchises with$2.6 billion in retail sales. And the trailer was viewed 158 million times in the 24 hours after it was released. So we'll see if that can make up for the disappointment of Snow White. So they're trying to say to you, Julia, look over here. Stitch is going to be great when Snow White was a bomb at the box office. Was there anything else specific to Snow White that critics are saying, you know, accounts for this dismal showing? Well, look, I think this is a complicated one.

30:47People are saying that the original story was just maybe too old and outdated. But I have to say, Melissa, that these family films are just a really different beast than other types of blockbusters. If you're going to be Mission Impossible, you're going to expect a big global opening. But if you're a family film, you might be able to hold up over the long run and deliver the results, you know, months and months later. Because parents with little kids want to find something to do. So interestingly, the audience score was a B +, which is not as good as Disney films usually are. But if you're looking at younger audiences under 18, the audience score was much higher.

31:22So, yes, some questions over whether it was even the right call to remake this movie. Disney has had a lot of success remaking their animated films in the past. This is a complicated one, but we'll see if it can pull off what Mufasa did, which was really outperforming over the long run, even after having a really disappointing debut. Julia, thanks. Julia Boorstin, I mean, when it comes to Disney, it's not just what goes on at the box office, obviously. With an uncertain consumer, what is going on with the parks? Not so much. Right, exactly, not so much. With streaming being so difficult in this environment in terms of spending, what goes on with Disney Plus?

31:57Yeah, all those good—I mean, and if the fate of Disney hangs on how well Snow White does, I think the stock is going a lot lower. I don't think it does, though, and I think at a certain point, just the valuation is too compelling. And all the things that you just mentioned correctly sell, I think, at this price and this valuation are priced in the name. I just love the audience gave it a B+. Have you ever taken your kids to the movie? They love everything. They think it's great. They think it's amazing. No matter what. They think everything is amazing. Unless they're afraid. But otherwise, no matter what, if they got popcorn, forget it.

32:25It was like an A++. You give them some gummy bears and solve the charts. I do think that the story around Disney Plus is actually good news. And this is, of course, the place that they really need to succeed. I'm not worried about studio. $350 million in marketing costs. And you used to call it Lilo and Stitch, right? Not Lila. Well, I'm a big fan of Lilo and Stitch. I know you love Lila. Lila is a different story. It's in the Parthenon. There's no question theme parks. We've heard about this with pricing. We've heard about this in terms of demand. It's going to be very difficult for theme parks to have the kind of year in 25, and we know they won't.

32:58But Disney +, everything we're learning in terms of profitability and where they put forecasts out there, I think this is a reason I own the stock. Coming up, five-star technicals, what the chart master sees for shares of Uber as the rideshare stock approaches a fork in the road. That's right ahead. But first, Structure Therapeutics CEO Ray Stevens will join us to lay out how his company is taking on the weight loss drug space and how advancements in GLP-1 pills are helping tip the scale. Fast Money is back in two.

33:31Welcome back to Fast Money. Structure Therapeutics shares more than 65 % off their 52-week high, despite positive updates in its weight loss portfolio. Last month, the company announced they completed enrollment for two studies focused on dosing its lead obesity pill candidate, set to accelerate the time it takes to get the drug to phase three trials, and raising the stakes for competition in the race to make an oral weight loss drug. For more, Structure CEO Ray Stevens joins us here on set. Ray, welcome to the show. Great to have you with us. Thank you, Melissa. It's great to be here in person.

33:59So we should be getting the readouts for the phase two access studies by year in 2025. Tell us about the actual drug and the molecule, because you say that it's a similar scaffolding to Lilly's candidate, oral candidate. Yeah. So Leniglipuron is the name of our drug. We're very excited about it. So we'll have two different phase two B readouts at the end of this year, access and access to. The first one, we believe, an ACCESS study will see equivalent to the best-in-class, potentially best-in-class, what's out there right now for oral, small-molecule pills. And the ACCESS, too, gives us the opportunity to potentially get even higher efficacy from that study.

34:39So we're really excited about both of these studies reading out at the end of the year. How do you think about the competition? Is it Lilly's candidate specifically? I mean, Pfizer's candidate is sort of pushed to the side for now. Is it Lilly's oral candidate? it? Is it injectables? Will it be Lily's Red of True Tide, for instance? Yeah, I think 2025 is going to be a really exciting year for patients, really, because they're finally going to have options. Right now, the options are injectable. And as you've said in the show before, most people discontinue injectables 85 % after two years. And so patients will finally get the chance to have options, an oral pill, a once-a-day oral pill.

35:17And as we talk to physicians, what they really want the most, flexibility. So the oral pills, giving that to their patients, being able to take the pill as they want based on tolerability. This will be a really exciting year. I think it'll be the year for oral GLP-1 small molecules. The way you're talking about it sounds like it will be a substitute for an injectable as opposed to an off-ramp from an injectable where you maintain weight. How are you seeing it fit into landscape now? I think it's really about giving patients options right now. The biggest option that's needed, accessibility. You know, we all have stories of somebody that we know that could not get access to these medicines.

35:53It's heartbreaking, the stories that you hear. And so being able to make these medicines accessible to people is really what drives us. And making an oral small molecule that can be manufactured, we're a small biotech company, we can manufacture 6 ,000 metric tons. That's enough for 120 million people today. That's more than Novo and Lilly can do combined. And so I think it's really about giving those patients the options. If they want to take the injectable once a week, there's convenience to that. If they want to take the oral pill once a day, there's that. And then we've talked before on the show about maintenance, and some people may want to switch, what we call, you know, switch studies, where what they're on an injectable, they may want to transition over to a once a day oral pill.

36:34Right. You've said that you are looking for a good partner. What does that mean? And is it specifically for this candidate, for the oral candidate? Does partnership also include, I don't know, an agreement, a takeover? What is it? Yeah. What we're driven by, you know, what we are really motivated by is making sure that we can get this medicine to as many people as possible. That's what drives us. We're going to make decisions based on that, plain and simple. So who has that large commercial ability, capability? That's really important. And so any partnership that we're having, you know, that we're thinking about really has to be about commercialization and getting this to the masses.

37:12I think some of the concerns, and correct me if I'm wrong, but the stock moved lower is on the back of 89 % experience nausea in the study. And, you know, I think that's maybe scaring not the investing community, but some of the trading community. Can you do anything to sort of assuage concerns of those people? Yeah, absolutely. It's a great question. So the reason why we've seen this, and Eli Lilly with Ofagliperon, and one of the other reasons we think 2025 is going to be the year of the small molecule is because Eli Lilly will read out their in Q2, their type 2 diabetes data, and in Q3, their healthy overweight data.

37:45And then we'll have in Q4, our healthy overweight data. What we're able to do in this time, in these longer time period studies, is we can titrate once every four weeks, where we give somebody the drug for four weeks at one dose, five milligrams, and then after four weeks, go up a dose. That allows the body to get used to these medicines. That's what one really needs. We've learned this from the from the injectable peptides. They inject, they go and titrate once every four weeks. Why do we think the oral pills are going to be any different? So finally, in 2025, we're going to get to see oral pills on the same titration schedule as the injectable peptides.

38:20When do you need to find this partner, Bai? I mean, if you're going to have phase two by the end of the year, you're going to be in phase, I mean, at some point, commercialization is very close. Yeah. So one of the things, you know, there's the old adage in biotech is raise money when you can, not when you need it. And we've executed on that flawlessly. So we're in a very good capital situation right now. We have runway until the end of 2027. And so we're able to complete our Phase IIb. We're already conducting some of the studies for Phase III readiness. Where we would really like to have that partner is really for commercialization and indication expansion.

38:55This is a medicine not just for chronic weight management, but we're seeing the improvements in cardiovascular, muscular kidney liver and we'll see later this year even cns diseases okay ray thanks for stopping by we appreciate it absolutely thank you ray stevens structured therapeutics coming up uber at a crossroads what the chart master sees next for the ride to your name and how the lines are drawing themselves on the chart don't go anywhere more fast money in two

39:26welcome back to fast money uber shares have been volatile over the past 12 months but the Chartmaster thinks it might be time to take the rideshare stock out for a drive. For more on this call, let's bring in Carter Braxton Worth of Worth Charting. Hey, Carter. Hi, Melissa. Yeah, we can go right to the charts. But what's important to note is this is a stock that's been range-bound for a year. You can see it here on the first. That's sideways, choppy, albeit, but sideways, is what a fallow asset is when the market's been going up. Every sector is up on a trillion-toeval basis, except energy. The market's up 10 percent, and this stock, bunch.

39:59Let's draw some lines. So they're all identical charts. The next iteration, that's a beautiful uptrend since 2022. We've checked back to the penny over and over and over, and we're down to trend yet again. If you add a downtrend line, you'll see we have some might call it a wedge, a trend. It doesn't know what you call it. It represents a standoff. And it's our judgment that it's likely soon to be resolved. Another way to draw the lines is, of course, to put a flat top on it. And that's an ascending wedge if you'd like to name your patterns. But that's what a breakout candidate is, something that's after a big move and churning sideways.

40:34Another way to draw the lines, all the same chart, would be as follows. Simply drawing the internal trend line in effect since the highs of 2020, the post-COVID bounce. And then finally, you can see this iteration. And you'll say, well, what is that? Some people like to name their patterns. These are setups. It doesn't matter whether you call it the so-called cup and handle. This is a bullish setup. We're playing for a breakout here. Uber, a fallow asset that we think is about to come to life. Fallow, correct, Carter? Not foul. Fallow. Just to clarify. Yes, was that right? Yes, okay. I've heard foul also.

41:12Much different. Thank you. Carter Braxton, worth charting. As I recall, you is the you in? In my tube. I love it in my tube, but it's going to continue to be there. And I will say this. I mean, with 15 percent. Why is that amusing? 15 % revenue growth, like 35 % EPS growth, reasonable valuation, back and filled to the level that it broke out from. It's got to get above 82. Otherwise, you have a bit of a technical problem. I think it does, Mel. By the way, if you want to talk to a guy about his tube. Excuse me? Or to Tim about his band. Or to Dan about his Gen AI and Quiz Karen about how she broke every single rule of the acronym game this year.

41:54You can sign up for our next edition of Fast Money Live. Our next live show is June 5th right here at the NASDAQ Market site. You can see the show, take part in a great Q &A, and then share a cocktail with your favorite trader. Scan the QR code on your screen or head over to cnvcevents.com slash fastmoney. I mean, an opportunity. Look, if Guy doesn't want to talk about his tube, I'll talk about it. She's not a bash. We're going to have a good time. The fact that you want to talk about Guy's tube is a little disturbing. Up next, final trades.

42:30Final trade time. Tim. I think PayPal was the P in Lysep last year. And it had a great run of the year. It pulled back significantly. I think the valuation is very attractive. New products coming online. Karen. Yes. Uber. I like to have fundamentals, but I like to hear that Carter loves it on the chart. And it was Spallow, not Baffle. Dan. Yeah, Nike's getting close there. Guy. GPCR is not in the tube because I don't know what letter I'd use, but I think it's going higher from here.

43:23make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.

From the publisher

Stocks jumping to start the week, as investors hope President Trump may be softening his stance on tariffs. If you can believe the bounce, and the sectors seeing the biggest gains. Plus One pharma company looking to tip the scales in the weight loss drug space. What the CEO of Structure Therapeutics sees next in GLP-1 development, and how an oral pill could be the key to success.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Stocks Surge To Start Week… And Structure Therapeutics CEO On Weight Loss Space 3/24/25CNBC's "Fast Money" · 44 min
Listen in VO